

NHS Providing up-to-date medical information for patients and healthcare professionals. Logged in as: [X] Logout Need help?

Home My Details My IBD Enter Symptoms Medicines Care Plan Nutrition Diagnostics Results Letters Contact Information

My IBD

- My IBD helps you keep a track of your inflammatory bowel disease. The information is provided from the records held at the hospital. If there are any obvious errors, please contact us by clicking here.
- The hospital is not able to keep an accurate list of your IBD medications. To complete your own personal up-to-date record, please enter your current medicines by clicking on the [Add New Medicine](#) icon in the Medicines section.

Primary Diagnosis:	Ulcerative colitis
Disease Extent:	Left Sided colitis
Year of Diagnosis:	2005
Complications:	Osteoporosis
Other parts of the body affected:	None
Weight:	57.6
IBD Related Family History:	Family history of bowel cancer
Surgical History:	None
Smoking History:	Previous smoker
Vaccination Record:	Previous history of chicken pox, Previous TB (BCG) vaccination
Year for Surveillance Colonoscopy:	2015
Nurses:	Cath Stanfield
Named Consultant:	Dr P Practice
Current Medications:	No current medicines

Legend: [Shaded Area] Represents the part of the bowel affected by your condition.

Abstract OC-082 Figure

Colorectal free papers

OC-083 FAECAL OCCULT BLOOD TEST ANALYSIS IN THE UNITED KINGDOM BOWEL CANCER SCREENING PROGRAMME

doi:10.1136/gutjnl-2013-304907.082

^{1,2}J Geraghty, ²J Snowball, ²P Butler, ¹S Sarkar, ³R Blanks, ²S Halloran, ⁴C Rees. ¹Royal Liverpool University Hospital, Liverpool; ²Southern Bowel Screening Hub, Guilford; ³Cancer Epidemiology Unit, University of Oxford, Oxford; ⁴South Tyneside NHS Foundation Trust, South Shields, UK

Introduction Increased vascularity of colorectal neoplasia creates bleeding detected by Faecal Occult Blood tests (FOBt). As bleeding is sporadic & unevenly distributed within stools, multiple testing may be required. UK bowel cancer screening programme (BCSP) kits contain 6 windows & subjects returning 5 or 6 positive results are termed "Abnormal" & referred to colonoscopy. If 1–4 windows are positive, the result is initially "Unclear" & 2 further kits are submitted, further positivity leads to colonoscopy ("Weak positive"). If no further blood is detected, subjects are deemed "Normal" & retested in 2 years.

Aim to study FOBt positivity in detail & whether particular patterns are associated with neoplasia rates that indicate the screening algorithm should be changed.

Methods We selected all subjects from one hub completing 2 screening episodes between 2007–9. Each episode included up to 3 kits and 18 windows. 95 possible combinations were identified. The number of positive windows compared to the total in a given episode was expressed as a "positivity ratio", ranging from 0–100%. Each combination leading to colonoscopy was analysed. Abnormal (83–100% positivity) & Unclear (11–83% positivity) groups were matched to neoplasia detection rates. Subjects with cancer detected in episode 2 following an Unclear result in episode 1, had their episode 1 pattern analysed.

Results FOBt from 284,387 subjects resulted in 4,000 colonoscopies, diagnosing 286 cancers. The overall cancer rate was 7.1% & adenoma rate 39.9%. The cancer rate was 21.3% in the Abnormal

group and 5.8% in the Weak positive group. Cancer detection increased from 1.9–24.5% in linear correlation with increasing positivity of windows, ranging from 11–83% of windows positive. Equivalent percentage positivity rates may or may not lead to colonoscopy depending on the particular pattern. A combination of 4 positive windows in kit 1 followed by 2 normal kits (4NN) equates to a positivity rate of 22% & is currently categorised in the Normal group & doesn't lead to colonoscopy. Other combinations with 22% window positivity do lead to colonoscopy & a cancer detection rate of 3%. There were 260 subjects with a 4NN combination in episode 1 not leading to colonoscopy & 5 of these subsequently had cancers detected following different combinations in episode 2.

Conclusion This study demonstrates higher ratios of positive windows; detect higher rates of cancer. At present, in the UK some subjects with 11% positive windows proceed to colonoscopy, while others with a rate of 22% (all at kit 1) do not. Based on these findings, further work examining the entire BCSP population, including the costs & benefits of changing the algorithm is in progress.

Disclosure of Interest None Declared

OC-084 A COMPARATIVE STUDY OF CLINICAL OUTCOMES AFTER LAPAROSCOPIC OR OPEN RESTORATIVE PROCTOCOLECTOMY

doi:10.1136/gutjnl-2013-304907.083

^{1,2}I White, ¹J T Jenkins, ¹R Coomber, ¹S K Clark, ¹R K S Phillips, ¹R H Kennedy. ¹Department of Surgery, St Mark's Hospital, London, UK

Introduction Laparoscopic colorectal surgery confers significant benefits over similar open procedures. A paucity of data exists examining this in restorative proctocolectomy, although recent literature has suggested reduced adhesions and improved fertility. We assessed consecutive patients undergoing laparoscopic ileal pouch anal anastomosis (IPAA), comparing clinical outcomes with those following conventional open surgery.

Methods 207 consecutive patients undergoing IPAA between November 2006 and November 2011 were assessed [76 (37%) laparoscopic procedures and 131 (67%) open cases were included].

A careful collaborative approach to developing the new technique was undertaken during the first two years in this high volume centre. Data were collected prospectively on a dedicated database. Study endpoints included post-operative length of stay, 30 day morbidity [Clavien-Dindo classification (C-D)], readmission, reoperation, pouch function & failure.

Results There were no significant differences in patient age, sex, BMI or previous abdominal surgery between the two groups. Conversion rate was 9%; Median operative time was significantly shorter for open surgery – 208 (IQR 178–255) versus 285 minutes (IQR 255–325); $p < 0.0005$. The duration of laparoscopic surgery decreased significantly during the study period.

Laparoscopy significantly reduced length of stay: median 6 days (IQR 4.25–8), v 8 days (IQR 7–12); $p < 0.0005$.

Minor [C-D I/II] complications were significantly reduced with laparoscopy (32.8% v 50.4%: OR 0.48 [95%CI 0.27–0.87]). Complications [all grades] were reduced non-significantly after laparoscopic surgery. There were no significant differences in total complications – 51.3% after laparoscopy versus 61.5%: OR 0.66 [95%CI 0.37–1.17], anastomotic leak rate, major morbidity, 30 day readmission, reoperation and stoma closure rates.

Pouch failure has occurred in 14 patients (7.7%) overall, however there were 12 (11%) in the open group with only 2 (2.6%) in the laparoscopic group, although this is not statistically significant ($P = 0.172$). No significant difference was seen in pouch dysfunction rates.

Conclusion Laparoscopic restorative proctocolectomy significantly reduces length of stay and minor morbidity and can be offered to an increasing proportion of restorative proctocolectomy patients. A careful collaborative developmental process has occurred in a high volume centre to achieve these results.

Disclosure of Interest I. White: None Declared, J. Jenkins: None Declared, R. Coomber: None Declared, S. Clark: None Declared, R. Phillips: None Declared, R. Kennedy Grant/Research Support from: Ethicon Endosurgery and Olympus UK

REFERENCE

Dindo D., Demartines N., Clavien P.A.; Classification of Surgical Complications. *Ann Surg*. 2004; 244: 931–937.

OC-085 PREDICTING LOCAL OR SYSTEMIC RECURRENCE AFTER CURATIVE RESECTION FOR COLORECTAL CANCER: THE ROLE OF ELASTICA STAINS TO OPTIMISE DETECTION OF VENOUS INVASION

doi:10.1136/gutjnl-2013-304907.084

¹E Wright, ¹C C McAteer, ¹D C McMillan, ¹P G Horgan, ²A K Foulis, ¹C S Roxburgh. ¹Academic Unit of Surgery, University of Glasgow; ²University Department of Pathology, NHS Greater Glasgow and Clyde, Glasgow, UK

Introduction Following colorectal cancer resection, high-risk tumour pathology guides provision of adjuvant therapy and follow-up. Currently, routinely assessed features include local invasion, nodal status, venous invasion (VI), serosal invasion, differentiation and margin status. It was recently reported that elastica tissue stains increase frequency of detection of VI to > 50%, reducing interobserver variation, increasing its prognostic value (Roxburgh 2010, Kirsch 2013). Given recurrence is either local, systemic or both, we sought to examine the role of routinely assessed pathological criteria including VI (detected using elastica) in determining recurrence following resection for colorectal cancer.

Methods From an institutional database 555 patients undergoing curative resection between 1997–2009 were identified with recurrence and follow-up data available. Pathology data was taken from reports issued at the time. VI was assessed prospectively with routine elastica staining for 417 patients and retrospectively in 138. Analysis was performed with binary logistic regression. Due to a

high number of comparisons, to enter the multivariate model a significance level of < 0.01 was used.

Results Of 555 patients, 141 (25%) developed recurrence. Frequency of VI detection was 54%. On logistic regression, elastica detected VI, T stage, lymph node involvement, serosal involvement, margin involvement, tumour perforation, peri-tumoural inflammation (Klintrup grade) and tumour necrosis were predictors of recurrence (any site, all $P < 0.05$). Differentiation was not. On multivariate analysis VI (OR 3.27, $P < 0.001$), lymph node involvement (OR 2.34, $P = 0.005$), serosal invasion (OR 2.38, $P = 0.005$), Klintrup grade (OR 0.68, $P = 0.037$) were independently predictors of recurrence. Most recurrence was systemic (75%). The same features predicted systemic recurrence as did overall recurrence but on multivariate analysis, only VI (OR 2.90, $P = 0.004$), lymph node involvement (OR 2.27, $P = 0.012$) and necrosis (OR 1.63, $P = 0.013$) were independent predictors of systemic recurrence. In the 35 cases of local recurrence VI, T stage, lymph node involvement, serosal involvement and margin involvement were significantly related ($P < 0.05$). On multivariate analysis, only VI (OR 2.28, $P = 0.057$) and T stage (OR 2.53, $P = 0.003$) were independent predictors.

Conclusion Whilst several pathological features predict local and systemic recurrence after surgery, VI detected at increased frequency (54%) with elastica stains was the only consistent, independent predictor of recurrence, at least as important as nodal spread. These results support implementation of routine measures such as elastica staining to optimise reporting of VI.

Disclosure of Interest None Declared

OC-086 SURVIVAL BENEFIT OF FDG-PET ORIENTED SURGERY FOR RECURRENT COLORECTAL CANCER

doi:10.1136/gutjnl-2013-304907.085

¹H Ishikawa, ¹A Watanabe, ¹T Mukogawa, ¹M Nakatani, ¹Y Nishiguchi, ¹M Matsusaka, ¹S Ko. ¹Surgery, Nara Prefectural Nara Hospital, Nara city, Japan

Introduction Pivotal treatment for localised recurrent colorectal cancer is surgical resection. Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has been accepted as an effective tool to identify disease localizations for patients with known or suspected recurrent colorectal cancer.

This study is to analyse the survival benefit of FDG-PET on the diagnosis and indication of surgical intervention for

Methods Consecutive 61 patients, with known or suspected recurrence of colorectal cancer based on elevation of tumour markers or abnormal findings on the follow-up CT image, underwent FDG-PET for 85 times between December 2003 and September 2009. Patients were aged between 39 and 94 years (median 66); 35 were male, 22 were Duke's A or B stage, and 31 had a history of colon cancer. The average period between operation and first FDG-PET was 24 months (range 4–114). Of 61 cases 50 had elevated serum CEA or CA19–9 (82.0%). For each case the diagnosis of FDG-PET image was compared with that of CT image and the final diagnosis.

Results Recurrence developed 2 times in average (range 1–6).

Of 61 patients five were identified recurrence by FDG-PET solely and indicated operation for 7 times. One of four shows disease-free survival for 70 months after common iliac replacement operation.

FDG-PET showed one false – positive and three false – negative findings. Totally, the sensitivity of FDG-PET was 93.3% and its accuracy was 91.8%, whereas those of CT were 85.0% and 83.6%, respectively.

Of 61 patients 19 had diffused disease spread by FDG-PET findings and were judged as contraindication of operation and the other 42 with localised disease spread received operation for 90 times (liver 28, lung 14, local 37, local with distant meta 5, etc.). Cumulative 1-year and 3-year survival ratios of operation cases after first recurrence were 95% and 80%, whereas, those of contraindication